Dacomitinib, Pfizer Inc’s experimental lung cancer drug, failed to show improvement in patients with advanced non-small cell lung cancer (NSCLC) in two late-stage studies. In the first trial, dacomitinib was inferior to another NSCLC drug when testing for improvement in survival time. In the second trial, it did not prolong the overall survival of patients compared to placebo. What are your current recommendations to treat patients with NSCLC?
For additional information, please click Reuters.
Image courtesy of [dream designs]/FreeDigitalPhotos.net.